A “Game of Thrones” in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Posi...

Por Pal, Sumanta Kumar, Vogelzang, Nicholas J.
Publicado em 2012

Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention

Por Moyad, Mark A, Vogelzang, Nicholas J
Publicado no Asian J Androl (2015)

Malignant mesothelioma advances in pathogenesis, diagnosis, and translational therapies /

Por Pass, Harvey I., Vogelzang, Nicholas J., Carbone, Michele.
Publicado em 2005

New and Promising Strategies in the Management of Bladder Cancer

Por Apolo, Andrea B., Vogelzang, Nicholas J., Theodorescu, Dan
Publicado no Am Soc Clin Oncol Educ Book (2015)

Effects of tumor burden reduction on survival in epithelioid malignant pleural mesothelioma

Por Mansfield, Aaron S., Peikert, Tobias, Vogelzang, Nicholas J., Symanowski, James T.
Publicado no Mayo Clin Proc (2018)

Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer

Por Halabi, Susan, Vogelzang, Nicholas J., Ou, San-San, Owzar, Kouros, Archer, Laura, Small, Eric J.
Publicado em 2009

Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm

Por Pal, Sumanta Kumar, Williams, Stephen, Josephson, David Y., Carmichael, Courtney, Vogelzang, Nicholas J., Quinn, David I.
Publicado em 2012

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA

Por Sartor, Oliver, Hoskin, Peter, Coleman, Robert E., Nilsson, Sten, Vogelzang, Nicholas J., Petrenciuc, Oana, Staudacher, Karin, Thuresson, Marcus, Parker, Christopher
Publicado no Prostate (2016)

CKD-EPI and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

Por Pal, Sumanta K., Ruel, Nora, Villegas, Sergio, Chang, Mark, DeWalt, Kara, Wilson, Timothy G., Vogelzang, Nicholas J., Yuh, Bertram E.
Publicado em 2014

Sequential Therapy in Metastatic Renal Cell Carcinoma

Por Hirsch, Bradford R., Burke, John M., Agrawal, Manish, Hauke, Ralph J., Hutson, Thomas E., Doshi, Gury, Fleming, Mark T., Vogelzang, Nicholas J.
Publicado no J Kidney Cancer VHL (2016)

Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)

Por Tsao, Anne S., Moon, James, Wistuba, Ignacio I., Vogelzang, Nicholas J., Kalemkerian, Gregory P., Redman, Mary W., Gandara, David R., Kelly, Karen
Publicado no J Thorac Oncol (2017)

A PHASE II STUDY OF ESTRAMUSTINE, DOCETAXEL, AND BEVACIZUMAB IN MEN WITH CASTRATE RESISTANT PROSTATE CANCER: RESULTS OF CANCER AND LEUKEMIA GROUP B (CALGB) 90006

Por Picus, Joel, Halabi, Susan, Kelly, W. Kevin, Vogelzang, Nicholas J., Whang, Young E., Kaplan, Ellen B., Stadler, Walter M., Small, Eric J.
Publicado em 2010

TUMOR VOLUME CHANGES ON 1.5 TESLA ENDORECTAL MRI DURING NEOADJUVANT ANDROGEN SUPPRESSION THERAPY FOR HIGHER-RISK PROSTATE CANCER AND RECURRENCE IN MEN TREATED USING RADIATION THERA...

Por D'Amico, Anthony V., Halabi, Susan, Tempany, Clare, Titelbaum, David, Philips, George K., Loffredo, Marian, McMahon, Elizabeth, Sanford, Ben, Vogelzang, Nicholas J., Small, Eric J.
Publicado em 2007

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis

Por Vogelzang, Nicholas J., Pal, Sumanta K., Ghate, Sameer R., Swallow, Elyse, Li, Nanxin, Peeples, Miranda, Zichlin, Miriam L., Meiselbach, Mark K., Perez, Jose Ricardo, Agarwal, Neeraj
Publicado no Adv Ther (2017)

Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer

Por Cheng, Heather H., Plets, Melissa, Li, Hongli, Higano, Celestia S., Tangen, Catherine M., Agarwal, Neeraj, Vogelzang, Nicholas J., Hussain, Maha, Thompson, Ian M., Tewari, Muneesh, Yu, Evan Y.
Publicado no Prostate (2017)

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

Por Wong, Risa L., Duong, Mai T., Tangen, Catherine M., Agarwal, Neeraj, Cheng, Heather H., Vogelzang, Nicholas J., Hussain, Maha, Thompson, Ian M., Quinn, David I., Yu, Evan Y.
Publicado no Prostate Cancer Prostatic Dis (2020)

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

Por Twardowski, Przemyslaw W., Tangen, Catherine M., Wu, Xiwei, Plets, Melissa R., Plimack, Elizabeth R., Agarwal, Neeraj, Vogelzang, Nicholas J., Wang, Jinhui, Tao, Shu, Thompson, Ian M., Lara, Primo
Publicado no Kidney Cancer (2017)

Cooperative group trials – Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Por Dorff, Tanya B., Tangen, Cathy M., Crawford, E. David, Petrylak, Daniel P., Higano, Celestia S., Raghavan, Derek, Quinn, David I., Vogelzang, Nicholas J., Thompson, Ian M., Hussain, Maha H.A.
Publicado em 2009

Quality of pathologic response and surgery correlate with survival for completely resected bladder cancer following neoadjuvant chemotherapy

Por Sonpavde, Guru, Goldman, Bryan H., Speights, V.O., Lerner, Seth P., Wood, David P., Vogelzang, Nicholas J., Trump, Donald L., Natale, Ronald B., Grossman, H. Barton, Crawford, E. David
Publicado em 2009

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma o...

Por Smith, David C., Tangen, Cathy M., Hussain, Maha H.A., Van Veldhuizen, Peter J., Harrer, Grant W., Stuart, Robert K., Mills, Glenn M., Vogelzang, Nicholas J., Thompson, Ian M.
Publicado em 2011